JP2002500181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500181A5 JP2002500181A5 JP2000527236A JP2000527236A JP2002500181A5 JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5 JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- riluzole
- per day
- composition according
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 9
- 229960004181 riluzole Drugs 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 208000001187 Dyskinesias Diseases 0.000 description 2
- 206010043118 Tardive dyskinesia Diseases 0.000 description 2
- 230000000561 anti-psychotic Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
IL122883 | 1998-01-09 | ||
IL127102 | 1998-11-17 | ||
IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002500181A JP2002500181A (ja) | 2002-01-08 |
JP2002500181A5 true JP2002500181A5 (ko) | 2006-03-02 |
Family
ID=26323572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000527236A Pending JP2002500181A (ja) | 1998-01-09 | 1999-01-05 | ジスキネジーの処置 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1043996A2 (ko) |
JP (1) | JP2002500181A (ko) |
KR (1) | KR20010033978A (ko) |
CN (1) | CN1290166A (ko) |
AU (1) | AU1780699A (ko) |
BR (1) | BR9906821A (ko) |
CA (1) | CA2317811A1 (ko) |
NO (1) | NO20003529L (ko) |
PL (1) | PL342098A1 (ko) |
WO (1) | WO1999034785A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161238A1 (fr) * | 1999-03-12 | 2001-12-12 | Aventis Pharma S.A. | Traitement de la sclerose laterale amyotrophique avec une association de riluzole et d'un antagoniste des recepteurs ampa |
FR2790670A1 (fr) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Association riluzole et antagoniste des recepteurs ampa |
US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
FR2809620B1 (fr) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie |
DE60100595T2 (de) * | 2001-05-08 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
-
1999
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Application Discontinuation
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/pt not_active IP Right Cessation
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/ja active Pending
- 1999-01-05 CN CN99802790A patent/CN1290166A/zh active Pending
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/ko not_active Application Discontinuation
- 1999-01-05 PL PL99342098A patent/PL342098A1/xx unknown
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
JO2555B1 (en) | Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent | |
HK1034898A1 (en) | Topical compositions for nsai drug delivery. | |
HK1034455A1 (en) | Oral pharmaceutical extended release dosage form. | |
WO2001019337A3 (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
AU2277101A (en) | Stable extended release oral dosage composition | |
AU2001283563A1 (en) | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent | |
AU7375598A (en) | Stable oral pharmaceutical dosage forms | |
HK1050839A1 (en) | Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state | |
SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
JP2002511411A5 (ko) | ||
YU14502A (sh) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
WO2006004449A3 (en) | A combination composition | |
AU1724301A (en) | Hydrogel-driven layered drug dosage form | |
AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
AU2003238221A1 (en) | Ibuprofen suspension | |
CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
JP2002522501A5 (ko) | ||
CA2350659A1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
JP2002500181A5 (ko) | ||
JP2001513504A5 (ko) | ||
AU2003290015A1 (en) | Mastitis treatment |